Mutation-resolved ABL1 inhibitor resistance prediction under mutation-disjoint and temporal cross-study validation
PLOS One · 2026
DOI: 10.1371/journal.pone.0353101 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Mohanad A Deif und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Sciences and Engineering, University of Sharjah, Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-abl, Drug Resistance, Neoplasm. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Computational prediction of ABL1 tyrosine-kinase inhibitor (TKI) resistance is difficult because available mutation–drug datasets are small, imbalanced, and heterogeneous. This study evaluates structure-aware resistance prediction under mutation-disjoint internal validation and temporal cross-study outcome validation. The development benchmark comprised 144 ABL1 mutation–TKI records (19 resistant and 125 susceptible) labelled by a ten-fold affinity-loss criterion. A fixed panel of 11 documented structural and energetic predictors was used to minimize data-adaptive feature selection within the validation framework. A calibrated ensemble combining Elastic-Net logistic regression, radial-basis-function support-vector machines, random forests, and XGBoost was evaluated using mutation-disjoint five-fold grouped out-of-fold prediction repeated ten times. Temporal validation used a later prime-editing resistance map, yielding 84 exact mutation–TKI matches across imatinib, nilotinib, bosutinib, and ponatinib; 61 had binary Sensitive/Resistant outcomes and 23 were retained as Intermediate. The 11-feature stack achieved grouped internal AUROC 0.645 (95% CI 0.429–0.830) and PR-AUC 0.230, with mean ± SD AUROC 0.583 ± 0.101 across repeated grouped splits. On the 61 binary later-study outcomes, AUROC was 0.605 (95% CI 0.431–0.874) and PR-AUC 0.835, modestly above the resistance-prevalence baseline of 0.770. External calibration was poor (Brier score 0.583; calibration slope 0.441). Elastic-Net showed somewhat higher temporal discrimination (AUROC 0.643; PR-AUC 0.877). These results indicate limited transportability across mutation identities and experimental platforms and support use of the framework for hypothesis-generating resistance screening rather than clinically calibrated treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Institute of Sciences and Engineering, University of Sharjah, Sharjah, United Arab Emirates.
- Department of Computer Science, College of Information Technology, Misr University for Science and Technology (MUST), Giza, Egypt.
- Faculty of Engineering, INTI International University, Nilai, Malaysia.
- Shinawatra University, Bangkok, Pathum Thani, Thailand.
- Applied Science Research Center, Applied Science Private University, Amman, Jordan.
- Department of Engineering, School of Science and Engineering, Glasgow Caledonian University, Glasgow, United Kingdom.
ORCID-Profile: Mohanad A Deif, Ahmed Solyman
Zitieren
APA
Deif, M. A., Hafez, M. A., Khishe, M., Solyman, A., & Elhaty, I. A. M. (2026). Mutation-resolved ABL1 inhibitor resistance prediction under mutation-disjoint and temporal cross-study validation. PLOS One. https://doi.org/10.1371/journal.pone.0353101
Vancouver
Deif MA, Hafez MA, Khishe M, Solyman A, Elhaty IAM. Mutation-resolved ABL1 inhibitor resistance prediction under mutation-disjoint and temporal cross-study validation. PLOS One. 2026. doi:10.1371/journal.pone.0353101
BibTeX
@article{Deif2026,
author = {Deif, Mohanad A and Hafez, Mohamed A and Khishe, Mohammad and Solyman, Ahmed and Elhaty, Ismail A M},
title = {Mutation-resolved ABL1 inhibitor resistance prediction under mutation-disjoint and temporal cross-study validation},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0353101}
}
EUVIMED